Clinical Trial Update: Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating ecallantide for the acute treatment of ACE inhibitor-induced angioedema; the current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioedema

Drugs mentioned

• KALBITOR (ecallantide)

Snippet

Sponsor: Bernstein, Jonathan A., M.D. | Conditions: Angioedema | Phase 2 | Status: UNKNOWN